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Introduction
The rapid rollout of antiretroviral therapy (ART) in resource-
limited settings over the last 7 years has ensured the treatment of 
millions of eligible HIV-infected individuals. ART responses in the 
majority of these individuals have been successful with robust changes 
in immunologic, clinical and virologic markers observed [1]. Due to 
increase in people receiving antiretroviral therapy (ART) the number 
of AIDS-related deaths has declined [2]. Since introduction of the ART, 
the disease has become in developing countries a chronic condition 
that can be managed for long term [3]. In recent years there is a 
growing awareness of the problems accompanying the use of HAART. 
In addition to drug resistance and difficulty of adhering to complex 
regimens, adverse effects associated with HAART have become a major 
concern [4]. In spite of ART benefits, adverse effects to these drugs have 
been pointed as one of the main reasons for discontinuation, switch 
and non-adherence [5]. From the previous studies, a study conducted 
in India resulted that in almost of 53.4% patients have developed at 
least one of the drug toxicity. The research conducted concluded that 
rash, peripheral neuropathy and anemia as the common adverse drug 
toxicities and that women are more likely to be experienced lactic 
acidosis [6]. Similarly in 2012 in Douala, Cameroon, a study revealed 
that, 66 (19.5%) of the 339 patients reported ADRs during HAART. 
Furthermore, authors suggest that caregivers should actively look for 
the HIV AIDS patients during HAART therapy and the introduction 
of newer generation drugs with low toxicity in resource constrained 
settings is mandatory [7]. 
In 2011, a study aimed to identify suspected adverse drug events 
on HAART therapy and showed 12.3% of ADRs prevalence. Further, 
it was revealed that prevalence of ADRs was higher in males (12.43%) 
compared to females (11.30%) among which peripheral neuropathy 
and anemia were highly prevalent adverse drug reaction [8]. Moreover, 
a retrospective cohort study was conducted by Roman et al showed 
that the study done with Filipinos in 2011 was that 24% of patients 
experienced ADRs. The most common ADRs were anemia, rashes and 
lactic acidosis. Authors concluded that most of the ADRs were due 
to the use of Zidovudine and it will fewer in ADRs if Zidovudine is 
replaced by Tenofovir in the first line treatment of HAART therapy [9]. 
A study conducted in western Uganda was done to evaluate gender 
differences in treatment outcomes. Researchers evaluated 305 patients 
with HIV/AIDS and found that females were more likely to have viral 
suppression as compared to male patients. Females had a significantly 
higher baseline CD4 cell count at initiation of treatment compared to 
male gender [10].
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Abstract
Aims and objective: Current study is aimed to explore and observe adverse drug reactions occurrence of 
antiretroviral therapy and to examine the gender differences in treatment outcomes of HIV/AIDS patients during 
HAART therapy. 
Method: An observational retrospective study of all patients on HAART therapy diagnosed with HIV infection from 
January 2007 to December 2012 was conducted at infectious disease department of Hospital Pulau Pinang, Malaysia. 
Patients socio-demographic, clinical and laboratory data was retrieved via self developed validated data collection 
form. 
Results: Out of 743 patients 571 (76.8%) were male and 172 (23.1%) were female patients. A total number of 425 
(57.2%) adverse drug reactions were reported among which 311 (73.1%) occurred in males and 114 (26.8%) in female 
patients, with a significant statistical relationship (p=0.02, OR=1.21). Out of total ADRs (57.2%) observed in both 
genders, a significant association was observed in Lipodystrophy (p=0.05), anemia (p=0.02), Peripheral Neuropathy 
(p=0.02) and pancreatitis (p=0.01). A total of 455 (79.6%) male and 139 (80.8%) female patients have improvement in 
CD4 cells count at the final follow up, a significant association (p=0.05) was observed among the mode of transmission 
and treatment outcome. 
Conclusion: Overall, the ADRs observed in both gender emphasize the importance of developing safer HAART 
regimens and managing these adverse effects in a timely manner in order to avoid long-term health consequences. 
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The relationship between sex and ART outcomes has been well 
studied in developed countries, but less so in resource-limited settings. 
Findings from studies conducted in developed countries are inconsistent, 
with some data showing improved clinical and/or viroimmunologic 
outcomes among women [11,12], whereas others show better outcomes 
among men or no significant sex difference at all [13,14]. In resource 
limited settings, worse outcomes have been more consistently observed 
in men, including a higher risk of incident opportunistic infections, 
mortality, immunologic and virologic failure [15,16]. In developing 
settings, men are more likely to have more advanced HIV at disease 
presentation, which is thought to place them at higher risk of adverse 
outcomes and less likely to respond well to ART [10]. To our knowledge, 
there has been no published data regarding adverse drug reactions 
and improvement of CD4 cells outcomes associated with HAART in 
Malaysian HIV/AIDS patients among genders. Here, we explore the 
capacity of patients on long-term HAART to improve CD4 cell counts 
and the commencement of different adverse drug reaction between the 
two genders and at different CD4 cell count. 
Methods 
Study design 
A retrospective cross-sectional observational study was conducted 
at infectious disease department of General Hospital Penang, Malaysia. 
Ethical approval 
The protocols were reviewed and approved by independent ethics 
committees and the National Medical Research Register (NMRR) in 
accordance to local regulations, notably regarding data protection. A 
letter of approval had been issued by NMRR for this study (NMRR-
13-1661-15774). As the study had a retrospective design and the data 
were not collected directly from the patient but instead taken from 
records, there was no need for patient consent. Patient records/data 
were anonymized and de-identified prior to analysis.
Data collection
All the HIV infected patients on HAART therapy from January 
2007 to December 2012 were included for the study. Pregnant women 
and children diagnosed with HIV were excluded from the study. The 
patient’s record forms were thoroughly reviewed and relevant data was 
noted on a validated data collection form. Demographic and clinical 
characteristics of patients that were susceptible to ADRs and with initial 
CD4 cells count after every follow-up were recorded and observed 
during the study period.
Statistical analysis
Categorical data was reported numerically as numbers and 
percentage of the total while continuous data was reported using mean 
and standard deviations (SD). Chi-square and Fischer’s exact tests were 
used to detect significance between categorical variables. Univariate 
analyses were also used for estimating further correlation between the 
ADRs and different variables. A p-value of 0.05 or below was considered 
statistically significant. 
All statistical calculations were performed using SPSS statistical 
package (Version 20). 
Results
A total of 997 patients were diagnosed as HIV infection between 
January 2007 and December 2012, of which 743 fulfilled our inclusion 
criteria. From the results a total of 314 (42.2%) patients had experienced 
one or more ADRs out of which 235 (74.8%) were male patients and 79 
(25.1%) were female. A statistically significant association (<0.001) was 
seen between weight and gender of the ADR patients in which most 
of the patients experienced ADRs were from weight group more than 
50 kg. Statistically significant association was also observed among the 
smoking status (<0.001), alcoholic status (<0.001) and drug abusers 
(0.005) with gender in patients ADRs were occurred. Most of the ADRs 
were observed in 187 (78.2) male smoker patients and 218 (91.3%) male 
patients with no drug addiction (Table 1). 
Overall 314 (42.2%) patients had experienced adverse drug 
reactions. A total number of 425 (57.2%) adverse drug reactions were 
reported among which 311 (73.1%) occurred in males and 114 (26.8%) 
in female patients. A statistical significant relationship was observed 
for gender and the occurrence of adverse drug reactions (p=0.002) 
(Table 1). Adverse drug reactions were also observed to be significantly 
associated with the patients mode of transmission (p=<0.001) and 
baseline CD4 cells count (p=0.03) (Table 2). 
The statistical relation of ADRs with weight (p=<0.001) and marital 
Socio-demographics Male N=235 (%) Female N=85 (%) *p- value
Age (years) 
<30 17 (7.9) 10 (12.9)
31-40 82 (35.1) 27 (34.1) 0.58
41-50 85 (35.6) 26 (32.9)
>50 51 (21.3) 16 (20)
Weight (kg)
30-40 kg 04 (1.6) 08 (10.5) <0.001
41-50 kg 82 (12.6) 28 (36.4)
Above 50 kg 203 (85.7) 43 (52.9)
Marital status
Single 93 (38.7) 05 (8.2)
Married 131 (56.5) 59 (71.7) <0.001
Widow/Divorced 11 (4.7) 15 (20)
Education status
Primary 131 (53.3) 31 (38.8)
Secondary 33 (15.8) 21 (25.9) 0.05
Graduation 20 (9.1) 04 (7.1)
No education 51 (21.7) 23 (28.2)
Employment level 
Employed 87 (36.3) 37 (45.9) 0.22**
Unemployed 146 (62.8) 42 (54.1)
Student 02 (0.8) 00 (00)
Smoking Status
No 48 (21.7) 57 (74.1) <0.001
Yes 187 (78.2) 22 (25.9)
Alcoholic Status
No 113 (47.4) 71 (87.1) <0.001
Yes 122 (52.6) 08 (12.9)
Drug Addiction
No 218 (91.3) 79 (100) 0.005
Yes 17 (8.7) 00 (00)
Heterosexual
No 57 (25.6) 24 (32.9) 0.19
Yes 178 (74.3) 55 (67.1)
Homo/Bi-sexual
No 211 (87.3) 79 (100) 0.001
Yes 24 (12.6) 00 (00)
*Chi Square test **Fisher exact test
Table 1: Gender base distribution of socio-demographic characteristics among 
ADR patients.
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status (p=<0.001) of the patients was also found significant (Table 1). 
However, on further analysis unmarried patients (OR=1.57, p=0.005), 
divorced patients (OR=0.20, p=0.03) and patients who had unknown 
mode of transmission (OR=2.04, p=0.01) shows significant association 
with ADRs (Table 3). 
Of total patients, 290 (39%) patients had baseline CD4 count 
between 200-350 cells/mm3, while 269 (36.2%) patients had baseline 
CD4 count less than 100 cells/mm3. There was a significant association 
(p=0.0001) between gender and baseline CD4 cells count (Table 
4). Univariate analysis further demonstrated a significant relation 
(OR=1.42, p=0.05 and OR=0.66, p=0.008, respectively) with patients 
whose baseline CD4 count was <100 and 200-350 cells/mm3 (Table 3).
Among 314 (42.2%) HIV patients, a total of 425 (57.2%) ADRs 
were recorded in which 311 (73.1%) ADRs were in male patients while 
114 (26.8%) were observed in female patients. Lipodystrophy (35.5%) 
was observed 29% in male and 5.8% in female. A statistically significant 
association was observed in Lipodystrophy (p=0.05), anemia (p=0.02), 
peripheral neuropathy (p=0.02), pancreatitis (p=0.01) and diarrhea 
with gender (Table 5). 
Among the total study population, 248 (92%) and 244 (84%) 











Male 571 (76.8) 235 (74.8) 311 (73.1) 0.002
Female 172 (23.1) 79 (25.1) 114 (26.8)
Age Group
<30 92 (12.3) 29 (9.2) 39 (9.1)
31-40 257 (34.5) 107 (34.07) 145 (34.1) 0.51
41-50 254 (34.1) 112 (35.6) 149 (35)
>50 140 (18.8) 66 (21) 92 (21.6)
Weight Group  
30-40 kg 24 (3.2) 13 (4.1) 13 (3) <0.001
41-50 kg 127 (17) 57 (18.1) 93 (21.8)
>50 kg 592 (79.6) 244 (77.7) 319 (75)
Marital Status
Single 261 (35.1) 94 (29.9) 124 (29.1)
Married 411 (55.3) 193 (61.4) 256 (60.2) <0.001
Divorced 52 (6.9) 25 (7.9) 39 (9.1)
Widowed 19 (2.5) 02 (0.6) 06 (1.4)
Education Status
Primary 350 (47.1) 159 (50.6) 214 (50.3)
Secondary 201 (27) 60 (19.1) 80 (18.8) 0.004
Graduation 65 (8.7) 29 (9.2) 41 (9.6)
No Education 127 (17) 66 (21) 90 (21.1)
Employment Status
Unemployed 263 (35.3) 114 (36.3) 156 (36.7) 0.34
Employed 465 (62.5) 198 (63) 267 (62.8)
Student 15 (2) 02 (0.6) 02 (0.4)
Mode of 
Transmission
Heterosexual 546 (73.4) 230 (73.2) 299 (70.3)
Homo/Bi-Sexual 83 (11.1) 30 (9.5) 38 (8.9) <0.001
IDU’s 56 (7.5) 20 (6.3) 32 (7.5)
Unknown 58 (7.8) 34 (10.8) 56 (13.1)
Baseline CD4 Cell 
Count
<100 269 (36.2) 122 (38.8) 169 (39.7)
100-200 146 (19.6) 72 (22.9) 92 (21.6) 0.036
200-350 290 (39) 105 (33.4) 145 (34.1)
>350 38 (5.1) 15 (4.7) 19 (4.4)
Table 2: Characteristics of HIV patients in Pulau Penang (n=743).
Characteristics Univariate Analysis
OR (95% CI) p-value*
Gender
Male 1.21 (0.86-1.71) 0.26
Female
Age Group
<30 0.59 (0.37-0.94) 0.02
31-40 0.96 (0.70-1.30) 0.80
41-50 1.12 (0.82-1.52) 0.46
>50 1.27 (0.88-1.48) 0.19
Weight Group
30-40 kg 0.68 (0.28-1.65) 0.40
41-50 kg 0.59 (0.26-1.34) 0.21
>50 kg 1.68 (0.74-3.82) 0.37
Marital Status
Single 0.67 (0.49- 0.91) 0.01
Married 1.54 (1.14-2.07) 0.004
Divorced 1.28 (0.73-2.26) 0.38
Widowed 0.15 (0.03-0.67) 0.01
Education Status
Primary 1.27 (0.95-1.71) 0.09
Secondary 0.48 (0.34-0.68) <0.001
Graduation 1.11 (0.66-1.85) 0.68
No Education 1.60 (1.09-2.35) 0.01
Employment Status
Unemployed 1.07 (0.79-1.45) 0.68
Employed 1.03 (0.76-1.39) 0.82
Student 0.20 (0.04-0.91) 0.03
Mode of Transmission
Heterosexual 0.97 (0.70-1.36) 0.90
Homo/Bi-Sexual 0.74 (0.46-1.20) 0.23
IDU’s 0.74 (0.42-1.30) 0.30
Unknown 2.04 (1.18-3.53) 0.01
Baseline CD4 Cell Count
<100 1.21 (0.90-1.64) 0.19
100-200 1.42 (0.99-2.05) 0.05
200-350 0.66 (0.49-0.89) 0.008
>350 0.88 (0.45-1.72) 0.72
Table 3: Univariate analysis of ADRs with patient characteristics.
Baseline CD4 Count Male (%) Female (%) p-value*
<100 229 (30.8) 40 (5.3)
100-200 113 (15.2) 33 (4.4) 0.0001
200-350 201 (27) 89 (11.9)
>350 28 (3.8) 10 (1.3)
Final CD4 Count
<100 50 (6.7) 08 (1.1)
100-200 77 (10.3) 21 (2.8) 0.101
200-350 110 (14.8) 26 (3.5)
>350 334 (44.9) 117 (15.7)
Table 4: CD4 cells count in Gender of the study population.
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increased whose baseline CD4 cells count were less than 100 cells/
mm3 and 200-350 cells/mm3 respectively. However 37 (98%) patients 
HAART therapy were failed whose CD4 cells count was more than 350 
cell/mm3 at baseline. Out of 546 (73.4%) patients who were diagnosed 
as heterosexual, 445 (83.3%) patients have successful HAART therapy. 
Moreover, 67 (80.7%) patients whose mode of transmission were 
homo/bi-sexual and 37 (66%) patients injecting drug users also have 
positive response to HAART therapy. Statistically significant relation 
was observed among the patients mode of transmission (p=0.05) and 
baseline CD4 cells count (<0.001) with treatment outcome of HAART 
therapy (Table 6).
Discussion 
The results of the current study showed that 42.6% patients 
experienced ADRs, out of which 31.9% were male and 10.7% were 
female patients with a higher rate in both adult male and female patients 
of age group 31-50 years. In contrast, most of the previous studies result 
in higher prevalence of ADRs among female than male patients [17-
19], however the observation support the result of higher prevalence 
rate of ADRs in age group 31-50 years of patients [17,20]. The results of 
ours study may be due to majority of the male patients in the current 
study. 
ADRs occurrence was high in married patients in both male and 
female patients. However, higher prevalence rate of 71.7% was observed 
in female married patients. These results are supported by the study 
conducted in Ethiopia [21]. The reason may be that majority of the HIV 
infected female patients were married. Majority of the male (53.3%) 
and female patients (38.8%) have at least a primary education. The same 
results were found in some African studies [22,23] as well as supported 
by previous study conducted in Malaysia [24]. This is most likely due 
to compulsory primary school education policy practice in Malaysia. 
Majority of the male patients (62.8%) that had experienced ADRs were 
unemployed and 54.1% of female patients are housewives. This result is 
supported by the previous study conducted in Uganda [10] which is in 
contrast with the study conducted in Malaysia [25]. 
The risk factor among ADRs group of patients were mostly 
heterosexual both in male (74.3%) and female (67.1%), however 
heterosexuality was slightly higher among male patients and other 
risk factor like homosexuality and IDU’s were overall in male patients. 
These results are supported by the study previously conducted in 
France, Uganda and Berlin, Germany [26-28]. Current study shows 
that majority of the patients of both male and female genders have their 
sexual risk factor and IDU’s and also majority of the overall patients have 
developed HIV infection through heterosexual, homo/bisexual and 
injecting drug use behavior. It may be due to the increasing awareness 
in sexuality and poor socioeconomic characteristics in Malaysia.
In the present study, the prevalence of ADRs was high in males as 
compared to female patients, same as the findings in Lihite et al. [29]. In 
contrast to our finding, Rajesh et al. [30] has found high prevalence of 
ADRs in females, when compared to males. The reason for differences 
in prevalence of ADRs among gender might be due to difference in 
body mass index and fat composition or hormonal effects on drug 
metabolism. In our study most of the patients were aged between 31-
40 years and 41-50 years; therefore we might have detected majority 
of ADRs from this group of patients. An ADRs observed in adults was 
similar to Mehta et al. [31], however Melmon [32] has reported large 
percentages of ADRs in geriatric and pediatric populations. Few studies 
from resource-limited settings have directly assessed the relationship 
of sex on HIV outcomes in response to ART, or factors associated with 
sex disparities in treatment outcomes. In a recent study from India 
[33], comparing sex differences in HAART outcomes, women had 
significantly higher CD4 cell counts after the completion of HAART 
therapy. In the present study a similar results (80.8%) were observed, 
though there was not any significant association (p=0.78) observed 






Vomiting 03 (0.7) 02 01 0.54
Diarrhea 06 (1.4) 02 04 0.02
Sleep Disorder 04 (0.9) 04 00 0.57
Dizziness 24 (5.6) 19 05 0.78
Rash 80 (18.8) 56 24 0.12
Lipodystrophy 151 (35.5) 126 25 0.05
Anemia 74 (17.4) 49 25 0.02
Peripheral Neuropathy 27 (6.3) 16 11 0.02
Itching 13 (3.05) 08 05 0.19
Pancreatitis 13 (3.05) 06 07 0.01
Weight loss 06 (1.4) 03 03 0.14
Lactic acidosis 08 (1.8) 06 02 0.90
Hepatotoxicity 07 (1.6) 05 02 0.66
Hepatic Steotasis 02 (0.4) 02 00 0.43
Blurred vision 05 (1.1) 05 00 0.59
Lethargy 02 (0.4) 02 00 0.43













Male 571 (76.8) 455 (79.6) 116 (20.3) 0.74
Female 172 (23.1) 139 (80.8) 33 (19.1)
Age Group
<30 92 (12.3) 78 (84.7) 14 (15.2)
31-40 257 (34.5) 198 (77) 59 (23) 0.20
41-50 254 (34.1) 210 (82.6) 44 (17.3)
>50 140 (18.8) 108 (77.1) 32 (22.9)
Weight Group
30-40 kg 24 (3.2) 22 (91.6) 02 (8.3) 0.26
41-50 kg 127 (17) 98 (77.1) 29 (22.9)
>50 kg 592 (79.6) 474 (80.1) 118 (19.9)
Marital Status
Single 261 (35.1) 210 (80.4) 51 (19.5)
Married 411 (55.3) 323 (78.5) 88 (21.4) 0.51
Divorced 52 (6.9) 44 (84.6) 08 (15.3)
Widowed 19 (2.5) 17 (89.4) 02 (10.6)
Mode of 
Transmission
Heterosexual 546 (73.4) 445 (83.3) 101 (18.4)
Homo/Bi-Sexual 83 (11.1) 67 (80.7) 16 (19.2) 0.05
IDU’s 56 (7.5) 37 (66) 19 (33.9)
Unknown 58 (7.8) 45 (77.5) 13 (22.4)
Baseline CD4 Cell 
Count
<100 269 (36.2) 248 (92) 21 (08)
100-200 146 (19.6) 101 (69.1) 45 (30.8) <0.001
200-350 290 (39) 244 (84) 46 (16)
>350 38 (5.1) 01 (02) 37 (98)
Table 6: Treatment outcome of HAART therapy based on CD4 cells count recovery.
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rural Uganda, women were more likely to have a lower mortality than 
men as well a higher rate of viral suppression, although the findings did 
not quite reach statistical significance [10,34]. In countries where there 
is considerably more data on the relationship between sex and HAART 
outcomes, most studies have found no sex differences in response 
to treatment [14,15] with a few showing more favorable responses 
in women [35,36]. Previous studies have identified age [37,38] and 
low baseline CD4 counts [39] as risk factors for incomplete CD4 cell 
recovery. However, the present study suggest an association of the 
mode of transmission to be the risk factor (p=0.05) which may be due 
to difference in the study design, duration of the study and inclusion 
criteria of the study. 
Sex discrepancies in treatment outcomes are thought to result 
from differences in both biologic and behavioral factors including 
antiretroviral metabolism, antiretroviral adherence and retention in 
care. Furthermore, Men have also been found to have a significantly 
higher rate of loss to follow-up and non-adherence to ART, with one 
study showing a direct correlation with HIV outcomes [34]. 
It has also been proposed that men respond less well to treatment 
because they are less adherent to care and ART [40]. There are 
few studies from resource-limited settings that have examined sex 
differences in adherence to ART and its association with treatment 
outcomes. In Zambia, no association was observed between sex and 
adherence to medications, defined as the number of antiretroviral doses 
taken out of the number of doses prescribed using pharmacy pick up 
records and pill counts [41]. 
In conclusion, results from this study lend further evidence of 
less favorable outcomes among both HIV-infected men and women. 
In this study, two important and potentially modifiable factors, level 
of immunosuppression at ART initiation and adverse drug reaction 
associated with HAART therapy significantly contribute to inferior 
outcomes in HIV patients, suggesting biologic differences between 
sexes may play a larger role. In developing settings, women continue 
to be the focus of healthcare interventions and these study findings 
should prompt HIV programs to now pay greater attention to men. 
Longer term studies of sex disparities in treatment outcomes should be 
conducted to help determine the most effective interventions to close 
this sex gap.
Conclusion
Overall, the high frequency of metabolic complications observed in 
both women and men emphasizes the importance of developing safer 
HAART regimens and managing these side effects in a timely manner 
in order to avoid long-term health consequences associated with such 
toxicities. 
Our study shows that both male and females in Penang, Malaysia 
on HAART have better treatment outcomes. The good clinical ART 
outcomes observed under standardized treatment protocols suggest 
that simply expanding access to treatment can have positive outcomes 
and also suggests that barriers to seeking and accessing treatment are 
being reduced. Therefore, it would be important to undertake a larger 
study to confirm the observed differences between genders in treatment 
outcomes. 
Study Limitations 
The study was conducted retrospectively by collecting any available 
data without gathering any information directly from the patient, due 
to this reason it was not possible to assess the disease severity and exact 
ADRs experienced by the patients. In addition some of the data were 
missing hence could not be added to further improve the strength of 
the findings.
Study Implications
Systemic procedure for updating patient’s profile in the hospital 
can be useful so that any crucial data of patient’s demographic 
characteristics, socioeconomic status, physical examination, etc., can be 
easily gathered. A large sampled prospective study would be essential to 
re-evaluate the findings of the present study focusing on various aspects 
of patient demographics, clinical parameters and ADRs in particular.
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